arrow
R

Richard Keen

metabolic bone disease
H指数:40
被引数:4,600

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quantitative Sensory Testing Reveals Evidence of Altered Pain Processing in Paget’s Disease of Bone

定量感觉测试揭示了骨Paget's病中疼痛处理发生改变的证据

2025-12-180
OAAI
Baseline Characteristics of the TOPaZ Study: Randomised Trial of Teriparatide and Zoledronic Acid Compared with Standard Care in Adults with Osteogenesis Imperfecta

TOPaZ研究基线特征:特立帕肽和唑来膦酸与标准护理在成骨不全成人中的随机对照试验

2025-11-080
OAAI
Real-World Effectiveness of Burosumab in Adults with X-Linked Hypophosphataemia (XLH) in the UK

英国X-连锁低磷酸盐血症(XLH)成年患者中Burosumab的真实世界有效性

2025-09-180
OAAI
Causes of Musculoskeletal Pain in Paget's Disease of Bone

佩吉特氏骨病的肌肉骨骼疼痛的原因

2024-09-300
OAAI
Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial
2024-08-311
OAAI
Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis
2024-05-182
OAAI
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

Garetosmab治疗进行性骨化性纤维发育不良: 一项随机、双盲、安慰剂对照2期试验

2023-09-2817
OAAI
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
2023-09-2717
OAAI
Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)
2023-01-2537
OA
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-Linked hypophosphataemia: rationale and description
2022-09-056
OAAI
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study
2022-08-0413
PRE